DC-based cancer vaccines

Journal of Clinical Investigation

Volumn 117, Issue 5, 2007, Pages 1195-1203

  Gilboa, Eli ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; DENDRITIC CELL VACCINE; IMIQUIMOD; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROSTAGLANDIN E2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; KIDNEY CANCER; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT FAILURE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 34248204110     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31205     Document Type: Review

References (104)

1. Banchereau, J., and Steinman, R.M. 1998. Dendritic cells and the control of immunity. Nature. 392:245-252.
2. Banchereau, J., et al. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811.
3. Reis e Sousa, C. 2001. Dendritic cells as sensors of infection. Immunity. 14:495-498.
4. Livingston, P.O. 1989. Experimental and clinical studies with active specific immunotherapy. Prog. Clin. Biol. Res. 288:309-321.
5. Gilboa, E. 2004. The promise of cancer vaccines. Nat. Rev. Cancer. 4:401-411.
6. Inaba, K., et al. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693-1702.
7. Banchereau, J., and Palucka, A.K. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5:296-306.
8. Nestle, F.O., Farkas, A., and Conrad, C. 2005. Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 17:163-169.
9. Schuler, G., Schuler-Thurner, B., and Steinman, R.M. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15:138-147.
10. Akira, S., Uematsu, S., and Takeuchi, O. 2006. Pathogen recognition and innate immunity. Cell. 124:783-801.
11. Adema, G.J., de Vries, I.J., Punt, C.J., and Figdor, C.G. 2005. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr. Opin. Immunol. 17:170-174.
12. Randolph, G.J., Angeli, V., and Swartz, M.A. 2005. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 5:617-628.
13. Iwasaki, A., and Medzhitov, R. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-995.
14. Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., and Lanzavecchia, A. 2005. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6:769-776.
15. Gautier, G., et al. 2005. A type I interferon autocrine-paracrine loop is involved in toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201:1435-1446.
16. Warger, T., et al. 2006. Synergistic activation of dendritic cells by combined toll-like receptor ligation induces superior CTL responses in vivo. Blood. 108:544-550.
17. Sporri, R., and Reis e Sousa, C. 2005. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol. 6:163-170.
18. O'Neill, D.W., Adams, S., and Bhardwaj, N. 2004. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 104:2235-2246.
19. Blander, J.M., and Medzhitov, R. 2006. On regulation of phagosome maturation and antigen presentation. Nat. Immunol. 7:1029-1035.
20. Wille-Reece, U., Wu, C.Y., Flynn, B.J., Kedl, R.M., and Seder, R.A. 2005. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol. 174:7676-7683.
21. Gavin, A.L., et al. 2006. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science. 314:1936-1938.
22. Gilboa, E. 2004. Knocking the SOCS1 off dendritic cells. Nat. Biotechnol. 22:1521-1522.
23. Shen, L., Evel-Kabler, K., Strube, R., and Chen, S.Y. 2004. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific antitumor immunity. Nat. Biotechnol. 22:1546-1553.
24. Cohen, N., et al. 2006. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood. 107:2037-2044.
25. Croft, M. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3:609-620.
26. Watts, T.H. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23:23-68.
27. Dannull, J., et al. 2005. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood. 105:3206-3213.
28. Ludewig, B., et al. 2001. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J. Immunol. 166:3678-3687.
29. He, Y., Zhang, J., Mi, Z., Robbins, P., and Falo, L.D., Jr. 2005. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J. Immunol. 174:3808-3817.
30. Ronchese, F., and Hermans, I.F. 2001. Killing of dendritic cells: a life cut short or a purposeful death? J. Exp. Med. 194:F23-F26.
31. Medema, J.P., et al. 2001. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J. Exp. Med. 194:657-667.
32. Kim, T.W., et al. 2003. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest. 112:109-117. doi:10.1172/JCI200317293.
33. Kim, T.W., et al. 2005. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 65:309-316.
34. Lanzavecchia, A. 1998. Immunology. Licence to kill. Nature. 393:413-414.
35. Grewal, I.S., and Flavell, R.A. 1998. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:111-135.
36. Schonbeck, U., and Libby, P. 2001. The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 58:4-43.
37. Langenkamp, A., Messi, M., Lanzavecchia, A., and Sallusto, F. 2000. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol. 1:311-316.
38. Reis e Sousa, C., et al. 1999. Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology. Immunity. 11:637-647.
39. Kalinski, P., Schuitemaker, J.H., Hilkens, C.M., Wierenga, E.A., and Kapsenberg, M.L. 1999. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J. Immunol. 162:3231-3236.
40. Hanks, B.A., et al. 2005. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat. Med. 11:130-137.
41. Jonuleit, H., et al. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27:3135-3142.
42. Schadendorf, D., et al. 2006. Dacarbazine (DTIC) versus vaccination with autologous peptidepulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann. Oncol. 17:563-570.
43. Scandella, E., Men, Y., Gillessen, S., Forster, R., and Groettrup, M. 2002. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood. 100:1354-1361.
44. Luft, T., et al. 2002. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood. 100:1362-1372.
45. Morelli, A.E., and Thomson, A.W. 2003. Dendritic cells under the spell of prostaglandins. Trends Immunol. 24:108-111.
46. Banerjee, D.K., Dhodapkar, M.V., Matayeva, E., Steinman, R.M., and Dhodapkar, K.M. 2006. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 108:2655-2661.
47. Mailliard, R.B., et al. 2004. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64:5934-5937.
48. Lu, W., Wu, X., Lu, Y., Guo, W., and Andrieu, J.M. 2003. Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 9:27-32.
49. Lu, W., Arraes, L.C., Ferreira, W.T., and Andrieu, J.M. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10:1359-1365.
50. Xu, S., et al. 2003. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J. Immunol. 171:2251-2261.
51. Dauer, M., et al. 2003. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170:4069-4076.
52. Lapenta, C., et al. 2006. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur. J. Immunol. 36:2046-2060.
53. Czerniecki, B.J., et al. 2007. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 67:1842-1852.
54. Nair, S., et al. 2003. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171:6275-6282.
55. Martin-Fontecha, A., et al. 2003. Regulation of den dritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. 198:615-621.
56. Thery, C., Zitvogel, L., and Amigorena, S. 2002. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2:569-579.
57. Zitvogel, L., et al. 1998. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4:594-600.
58. Carbone, F.R., Belz, G.T., and Heath, W.R. 2004. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol. 25:655-658.
59. Kovar, M., et al. 2006. Direct stimulation of T cells by membrane vesicles from antigen-presenting cells. Proc. Natl. Acad. Sci. U. S. A. 103:11671-11676.
60. Jenne, L., Schuler, G., and Steinkasserer, A. 2001. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol. 22:102-107.
61. Gilboa, E., and Vieweg, J. 2004. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199:251-263.
62. Nair, S.K., et al. 1998. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 16:364-369.
63. Nair, S.K., et al. 2000. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. 6:1011-1017.
64. Heiser, A., et al. 2000. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol. 164:5508-5514.
65. Heiser, A., et al. 2002. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109:409-417. doi:10.1172/JCI200214364.
66. Su, Z., et al. 2005. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 174:3798-3807.
67. Vambutas, A., et al. 2005. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a preclinical cottontail rabbit papillomavirus model. Vaccine. 23:5271-5280.
68. Van Tendeloo, V.F., et al. 2001. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 98:49-56.
69. Yewdell, J.W., Norbury, C.C., and Bennink, J.R. 1999. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73:1-77.
70. Wu, T.C., et al. 1995. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. U. S. A. 92:11671-11675.
71. Wang, R.F. 2001. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 22:269-276.
72. Leifert, J.A., Rodriguez-Carreno, M.P., Rodriguez, F., and Whitton, J.L. 2004. Targeting plasmid-encoded proteins to the antigen presentation pathways. Immunol. Rev. 199:40-53.
73. Yewdell, J.W., and Nicchitta, C.V. 2006. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol. 27:368-373.
74. Barry, M.A., Howell, D.P., Andersson, H.A., Chen, J.L., and Singh, R.A. 2004. Expression library immunization to discover and improve vaccine antigens. Immunol. Rev. 199:68-83.
75. Grunebach, F., Muller, M.R., Nencioni, A., and Brossart, P. 2003. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther. 10:367-374.
76. Alexander-Miller, M.A., Leggatt, G.R., and Berzofsky, J.A. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 93:4102-4107.
77. Alexander-Miller, M.A., Leggatt, G.R., Sarin, A., and Berzofsky, J.A. 1996. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184:485-492.
78. Anderton, S.M., Radu, C.G., Lowrey, P.A., Ward, E.S., and Wraith, D.C. 2001. Negative selection during the peripheral immune response to antigen. J. Exp. Med. 193:1-11.
79. Bullock, T.N., Mullins, D.W., and Engelhard, V.H. 2003. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J. Immunol. 170:1822-1829.
80. Rees, W., et al. 1999. An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc. Natl. Acad. Sci. U. S. A. 96:9781-9786.
81. Valmori, D., et al. 2002. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J. Immunol. 168:4231-4240.
82. Zeh, H.J., 3rd, Perry-Lalley, D., Dudley, M.E., Rosenberg, S.A., and Yang, J.C. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162:989-994.
83. Busch, D.H., Kerksiek, K.M., and Pamer, E.G. 2000. Differing roles of inflammation and antigen in T cell proliferation and memory generation. J. Immunol. 164:4063-4070.
84. Bachmann, M.F., et al. 2006. Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur. J. Immunol. 36:842-854.
85. Wilson, N.S., and Villadangos, J.A. 2005. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv. Immunol. 86:241-305.
86. Wang, R.F., and Wang, H.Y. 2002. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat. Biotechnol. 20:149-154.
87. Morse, M.A., Lyerly, H.K., Gilboa, E., Thomas, E., and Nair, S.K. 1998. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res. 58:2965-2968.
88. Schaft, N., et al. 2005. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J. Immunol. 174:3087-3097.
89. Gilboa, E. 1999. The makings of a tumor rejection antigen. Immunity. 11:263-270.
90. Schmitz, M., et al. 2000. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 60:4845-4849.
91. Cranmer, L.D., Trevor, K.T., and Hersh, E.M. 2004. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol. Immunother. 53:275-306.
92. Lesterhuis, W.J., de Vries, I.J., Adema, G.J., and Punt, C.J. 2004. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann. Oncol. 15(Suppl. 4):iv145-iv151.
93. Fay, J.W., et al. 2006. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol. Immunother. 55:1209-1218.
94. Su, Z., et al. 2003. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63:2127-2133.
95. Dannull, J., et al. 2005. Enhancement of vaccin-emediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115:3623-3633. doi:10.1172/JCI25947.
96. De Vries, I.J., et al. 2003. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63:12-17.
97. Masopust, D., Ha, S.J., Vezys, V., and Ahmed, R. 2006. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J. Immunol. 177:831-839.
98. Pozzi, L.A., Maciaszek, J.W., and Rock, K.L. 2005. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J. Immunol. 175:2071-2081.
99. Zanetti, M., Castiglioni, P., Rizzi, M., Wheeler, M., and Gerloni, M. 2004. B lymphocytes as antigen-presenting cell-based genetic vaccines. Immunol. Rev. 199:264-278.
100. Brandes, M., Willimann, K., and Moser, B. 2005. Professional antigen-presentation function by human gammadelta T Cells. Science. 309:264-268.
101. Korman, A.J., Peggs, K.S., and Allison, J.P. 2006. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90:297-339.
102. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer. 5:263-274.
103. Zitvogel, L., Tesniere, A., and Kroemer, G. 2006. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6:715-727.
104. Baecher-Allan, C., and Anderson, D.E. 2006. Immune regulation in tumor-bearing hosts. Curr. Opin. Immunol. 18:214-219.